Other
ECC
ECC is an intervention with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
OTHER
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
2
40%
Ph not_applicable
2
40%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 3Large-scale testing
2(50.0%)
N/ANon-phased studies
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Other(1)
Detailed Status
Completed4
unknown1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 32 (50.0%)
N/A2 (50.0%)
Trials by Status
completed480%
unknown120%
Recent Activity
0 active trials
Showing 5 of 5
completed
Diagnostics and Quality of Life With EIA and EILO
NCT03550456
completednot_applicable
Influence of Umbilical Cord Clamping Time in the Newborn
NCT03624335
unknownphase_3
The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection
NCT03366493
completednot_applicable
Calmer Life: Testing the Effectiveness of a Treatment for Anxiety
NCT01702220
completedphase_3
Metastatic Gastric Cancer FFCD 03-07
NCT00374036
Clinical Trials (5)
Showing 5 of 5 trials
NCT03550456
Diagnostics and Quality of Life With EIA and EILO
NCT03624335Not Applicable
Influence of Umbilical Cord Clamping Time in the Newborn
NCT03366493Phase 3
The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection
NCT01702220Not Applicable
Calmer Life: Testing the Effectiveness of a Treatment for Anxiety
NCT00374036Phase 3
Metastatic Gastric Cancer FFCD 03-07
All 5 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 5